Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis

Won Jung Koh; Seung Heon Lee; Young Ae Kang; Chang Hoon Lee; Jae Chol Choi; Jae Ho Lee; Seung Hun Jang; Kwang Ha Yoo; Ki Hwan Jung; Ki Uk Kim; Sang Bong Choi; Yon Ju Ryu; Kyung Chan Kim; Soojung Um; Yong Soo Kwon; Yee Hyung Kim; Won Il Choi; Kyeongman Jeon; Yong Il Hwang; Se Joong Kim; Young Seok Lee; Eun Young Heo; Juhee Lee; Yeo WoonKi; Tae Sun Shim; Jae Joon Yim

doi:10.1164/rccm.201303-0604OC

Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis

Won Jung Koh, Seung Heon Lee, Young Ae Kang, Chang Hoon Lee, Jae Chol Choi, Jae Ho Lee, Seung Hun Jang, Kwang Ha Yoo, Ki Hwan Jung, Ki Uk Kim, Sang Bong Choi, Yon Ju Ryu, Kyung Chan Kim, Soojung Um, Yong Soo Kwon, Yee Hyung Kim, Won Il Choi, Kyeongman Jeon, Yong Il Hwang, Se Joong KimYoung Seok Lee, Eun Young Heo, Juhee Lee, Yeo WoonKi, Tae Sun Shim, Jae Joon Yim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in theMXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in theMXF group (P = 0.75). Conclusions:ThechoiceofLFXorMXFfortreatmentofpatientswithMDRTB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).

Original language	English
Pages (from-to)	858-864
Number of pages	7
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	188
Issue number	7
DOIs	https://doi.org/10.1164/rccm.201303-0604OC
State	Published - 1 Oct 2013

Keywords

Fluoroquinolone
Levofloxacin
Moxifloxacin
Multidrug-resistant tuberculosis

Access to Document

10.1164/rccm.201303-0604OC

Cite this

Koh, W. J., Lee, S. H., Kang, Y. A., Lee, C. H., Choi, J. C., Lee, J. H., Jang, S. H., Yoo, K. H., Jung, K. H., Kim, K. U., Choi, S. B., Ryu, Y. J., Kim, K. C., Um, S., Kwon, Y. S., Kim, Y. H., Choi, W. I., Jeon, K., Hwang, Y. I., ... Yim, J. J. (2013). Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine, 188(7), 858-864. https://doi.org/10.1164/rccm.201303-0604OC

@article{f15d044abafa46fa99f48c2910f7c4a5,

title = "Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis",

abstract = "Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in theMXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in theMXF group (P = 0.75). Conclusions:ThechoiceofLFXorMXFfortreatmentofpatientswithMDRTB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).",

keywords = "Fluoroquinolone, Levofloxacin, Moxifloxacin, Multidrug-resistant tuberculosis",

author = "Koh, {Won Jung} and Lee, {Seung Heon} and Kang, {Young Ae} and Lee, {Chang Hoon} and Choi, {Jae Chol} and Lee, {Jae Ho} and Jang, {Seung Hun} and Yoo, {Kwang Ha} and Jung, {Ki Hwan} and Kim, {Ki Uk} and Choi, {Sang Bong} and Ryu, {Yon Ju} and Kim, {Kyung Chan} and Soojung Um and Kwon, {Yong Soo} and Kim, {Yee Hyung} and Choi, {Won Il} and Kyeongman Jeon and Hwang, {Yong Il} and Kim, {Se Joong} and Lee, {Young Seok} and Heo, {Eun Young} and Juhee Lee and Yeo WoonKi and Shim, {Tae Sun} and Yim, {Jae Joon}",

year = "2013",

month = oct,

day = "1",

doi = "10.1164/rccm.201303-0604OC",

language = "English",

volume = "188",

pages = "858--864",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "7",

}

Koh, WJ, Lee, SH, Kang, YA, Lee, CH, Choi, JC, Lee, JH, Jang, SH, Yoo, KH, Jung, KH, Kim, KU, Choi, SB, Ryu, YJ, Kim, KC, Um, S, Kwon, YS, Kim, YH, Choi, WI, Jeon, K, Hwang, YI, Kim, SJ, Lee, YS, Heo, EY, Lee, J, WoonKi, Y, Shim, TS & Yim, JJ 2013, 'Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis', American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 7, pp. 858-864. https://doi.org/10.1164/rccm.201303-0604OC

TY - JOUR

T1 - Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis

AU - Koh, Won Jung

AU - Lee, Seung Heon

AU - Kang, Young Ae

AU - Lee, Chang Hoon

AU - Choi, Jae Chol

AU - Lee, Jae Ho

AU - Jang, Seung Hun

AU - Yoo, Kwang Ha

AU - Jung, Ki Hwan

AU - Kim, Ki Uk

AU - Choi, Sang Bong

AU - Ryu, Yon Ju

AU - Kim, Kyung Chan

AU - Um, Soojung

AU - Kwon, Yong Soo

AU - Kim, Yee Hyung

AU - Choi, Won Il

AU - Jeon, Kyeongman

AU - Hwang, Yong Il

AU - Kim, Se Joong

AU - Lee, Young Seok

AU - Heo, Eun Young

AU - Lee, Juhee

AU - WoonKi, Yeo

AU - Shim, Tae Sun

AU - Yim, Jae Joon

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in theMXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in theMXF group (P = 0.75). Conclusions:ThechoiceofLFXorMXFfortreatmentofpatientswithMDRTB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).

AB - Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in theMXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in theMXF group (P = 0.75). Conclusions:ThechoiceofLFXorMXFfortreatmentofpatientswithMDRTB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).

KW - Fluoroquinolone

KW - Levofloxacin

KW - Moxifloxacin

KW - Multidrug-resistant tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84886289933&partnerID=8YFLogxK

U2 - 10.1164/rccm.201303-0604OC

DO - 10.1164/rccm.201303-0604OC

M3 - Article

C2 - 23927582

AN - SCOPUS:84886289933

SN - 1073-449X

VL - 188

SP - 858

EP - 864

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

IS - 7

ER -

Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this